Tilray | TRLY - Sales Revenues

Stock Price
7.28
Daily Change
-0.26 -3.45%
Monthly
-22.22%
Yearly
970.59%
Q2 Forecast
7.13

Tilray reported $217.51M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acasti Pharma USD -4.76M 4.76M Dec/2024
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Alaunos Therapeutics USD 2K 2K Mar/2025
Aurora Cannabis CAD 94.19M 3.82M Dec/2025
Avita Medical AUD 17.61M 805K Dec/2025
Canopy Growth CAD 74.54M 7.86M Dec/2025
Cronos Group USD 58.97M 580K Mar/2026
Dianthus Therapeutics USD 284K 112K Dec/2025
Divis Laboratories Ltd INR 26.04B 1.11B Dec/2025
Ionis Pharmaceuticals USD 246M 43M Mar/2026
IQVIA Holdings USD 4.15B 210M Mar/2026
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
Moderna USD 389M 289M Mar/2026
Organigram Holdings CAD 63.54M 16.52M Dec/2025
Organon & Co USD 1.46B 50M Mar/2026
Revvity USD 711M 61.06M Mar/2026
Tectonic Therapeutic USD 0 0 Dec/2024
Tilray USD 217.51M 74.75M Dec/2025
Viatris USD 3.52B 180M Mar/2026
Xeris Pharmaceuticals USD 83.13M 2.68M Mar/2026
Zealand Pharma A/S 68.91M 19.35M Dec/2025